A detailed history of Morse Asset Management, Inc transactions in Vertex Pharmaceuticals Inc stock. As of the latest transaction made, Morse Asset Management, Inc holds 9,977 shares of VRTX stock, worth $4.5 Million. This represents 1.05% of its overall portfolio holdings.

Number of Shares
9,977
Previous 10,003 0.26%
Holding current value
$4.5 Million
Previous $4.65 Million 0.26%
% of portfolio
1.05%
Previous 1.0%

Shares

27 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 20, 2024

SELL
$460.0 - $505.78 $11,960 - $13,150
-26 Reduced 0.26%
9,977 $4.64 Million
Q3 2024

Nov 14, 2024

BUY
$460.0 - $505.78 $4.6 Million - $5.06 Million
10,003 New
10,003 $4.65 Million
Q2 2024

Aug 14, 2024

SELL
$392.81 - $485.53 $31,424 - $38,842
-80 Reduced 0.78%
10,115 $4.74 Million
Q1 2024

May 15, 2024

BUY
$407.69 - $446.08 $287,829 - $314,932
706 Added 7.44%
10,195 $4.26 Million
Q4 2023

Feb 15, 2024

BUY
$343.0 - $410.68 $530,621 - $635,321
1,547 Added 19.48%
9,489 $3.86 Million
Q3 2023

Nov 13, 2023

BUY
$338.18 - $362.46 $210,009 - $225,087
621 Added 8.48%
7,942 $2.76 Million
Q2 2023

Aug 14, 2023

BUY
$314.42 - $351.91 $448,048 - $501,471
1,425 Added 24.17%
7,321 $2.58 Million
Q1 2023

May 03, 2023

BUY
$283.23 - $323.1 $192,879 - $220,031
681 Added 13.06%
5,896 $1.86 Million
Q4 2022

Feb 08, 2023

BUY
$285.76 - $321.48 $365,201 - $410,851
1,278 Added 32.46%
5,215 $1.51 Million
Q3 2022

Nov 14, 2022

BUY
$273.83 - $305.53 $576,412 - $643,140
2,105 Added 114.9%
3,937 $1.14 Million
Q2 2022

Aug 11, 2022

BUY
$234.96 - $292.55 $88,110 - $109,706
375 Added 25.74%
1,832 $516,000
Q1 2022

May 12, 2022

BUY
$221.42 - $260.97 $322,608 - $380,233
1,457 New
1,457 $380,000
Q1 2021

May 13, 2021

SELL
$207.02 - $241.31 $262,501 - $305,981
-1,268 Closed
0 $0
Q4 2020

Feb 11, 2021

SELL
$207.01 - $276.09 $2.01 Million - $2.68 Million
-9,710 Reduced 88.45%
1,268 $300,000
Q3 2020

Nov 09, 2020

BUY
$255.65 - $303.1 $616,372 - $730,774
2,411 Added 28.14%
10,978 $2.99 Million
Q2 2020

Aug 14, 2020

BUY
$225.48 - $295.8 $1.09 Million - $1.43 Million
4,837 Added 129.68%
8,567 $2.49 Million
Q1 2020

May 01, 2020

BUY
$199.77 - $247.81 $483,243 - $599,452
2,419 Added 184.52%
3,730 $888,000
Q4 2019

Jan 31, 2020

BUY
$166.71 - $223.91 $218,556 - $293,546
1,311 New
1,311 $287,000
Q3 2019

Nov 05, 2019

SELL
$166.23 - $187.09 $1.6 Million - $1.8 Million
-9,628 Closed
0 $0
Q2 2019

Aug 01, 2019

SELL
$164.61 - $190.37 $474,076 - $548,265
-2,880 Reduced 23.03%
9,628 $1.77 Million
Q1 2019

May 02, 2019

BUY
$163.73 - $194.7 $1.11 Million - $1.32 Million
6,795 Added 118.94%
12,508 $2.3 Million
Q4 2018

Feb 13, 2019

SELL
$151.91 - $192.21 $1.53 Million - $1.94 Million
-10,102 Reduced 63.88%
5,713 $947,000
Q3 2018

Nov 01, 2018

BUY
$167.73 - $192.74 $1.64 Million - $1.88 Million
9,764 Added 161.36%
15,815 $3.05 Million
Q2 2018

Aug 15, 2018

BUY
$145.72 - $169.96 $98,361 - $114,723
675 Added 12.56%
6,051 $1.03 Million
Q1 2018

May 02, 2018

BUY
$151.6 - $177.13 $6,973 - $8,147
46 Added 0.86%
5,376 $876,000
Q4 2017

Jan 29, 2018

BUY
$137.28 - $155.55 $24,710 - $27,999
180 Added 3.5%
5,330 $799,000
Q3 2017

Oct 31, 2017

BUY
$148.13 - $162.24 $762,869 - $835,536
5,150
5,150 $783,000

Others Institutions Holding VRTX

About VERTEX PHARMACEUTICALS INC


  • Ticker VRTX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 256,691,008
  • Market Cap $116B
  • Description
  • Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAF...
More about VRTX
Track This Portfolio

Track Morse Asset Management, Inc Portfolio

Follow Morse Asset Management, Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Morse Asset Management, Inc, based on Form 13F filings with the SEC.

News

Stay updated on Morse Asset Management, Inc with notifications on news.